This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Burman, P. Articles by Lindgren, A. C. Search for Related Content PubMed PubMed Citation Articles by Burman, P. Articles by Lindgren, A. C.

Endocrine Dysfunction in Prader-Willi Syndrome: A Review with Special Reference to GH

Pharmacia Corporation, SE-112 87 Stockholm, Sweden (P.B.) and Department of Woman and Child Health, Karolinska Institute, SE-171 76 Stockholm, Sweden (E.M.R., A.C.L.)

Correspondence: Address all correspondence and requests for reprints to: Pia Burman, M.D., Ph.D., Pharmacia Corporation, Lindhagensgatan 126, SE-112 87 Stockholm, Sweden. E-mail: pia.burman{at}eu.pnu.com

Prader-Willi syndrome is a genetic disorder occurring in 1 in 10,000–16,000 live-born infants. In the general population, approximately 60 people in every 1,000,000 are affected. The condition is characterized by short stature, low lean body mass, muscular hypotonia, mental retardation, behavioral abnormalities, dysmorphic features, and excessive appetite with progressive obesity. Furthermore, morbidity and mortality are high, probably as a result of gross obesity. Most patients have reduced GH secretory capacity and hypogonadotropic hypogonadism, suggesting hypothalamic-pituitary dysfunction. Replacement of GH and/or sex hormones may therefore be beneficial in Prader-Willi syndrome, and several clinical trials have now evaluated GH replacement therapy in affected children. Results of GH treatment have been encouraging: improved growth, increased lean body mass, and reduced fat mass. There was also some evidence of improvements in respiratory function and physical activity. The long-term benefits of GH treatment are, however, still to be established. Similarly, the role of sex hormone replacement therapy needs to be clarified as few data exist on its efficacy and potential benefits. In summary, Prader-Willi syndrome is a disabling condition associated with GH deficiency and hypogonadism. More active treatment of these endocrine disorders is likely to benefit affected individuals.

This article has been cited by other articles:

				N. L.G. Miller, R. Wevrick, and P. L. Mellon Necdin, a Prader-Willi syndrome candidate gene, regulates gonadotropin-releasing hormone neurons during development Hum. Mol. Genet., January 15, 2009; 18(2): 248 - 260. [Abstract] [Full Text] [PDF]

				G. Diene, J. S. de Gauzy, and M. Tauber Is scoliosis an issue for giving growth hormone to children with Prader-Willi syndrome? Arch. Dis. Child., December 1, 2008; 93(12): 1004 - 1006. [Full Text] [PDF]

				A. P. Goldstone, A. J. Holland, B. P. Hauffa, A. C. Hokken-Koelega, M. Tauber, and on behalf of speakers contributors at the Second E Recommendations for the Diagnosis and Management of Prader-Willi Syndrome J. Clin. Endocrinol. Metab., November 1, 2008; 93(11): 4183 - 4197. [Abstract] [Full Text] [PDF]

				E. Feigerlova, G. Diene, F. Conte-Auriol, C. Molinas, I. Gennero, J.-P. Salles, C. Arnaud, and M. Tauber Hyperghrelinemia Precedes Obesity in Prader-Willi Syndrome J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2800 - 2805. [Abstract] [Full Text] [PDF]

				H. R. Mogul, P. D. K. Lee, B. Y. Whitman, W. B. Zipf, M. Frey, S. Myers, M. Cahan, B. Pinyerd, and A. L. Southren Growth Hormone Treatment of Adults with Prader-Willi Syndrome and Growth Hormone Deficiency Improves Lean Body Mass, Fractional Body Fat, and Serum Triiodothyronine without Glucose Impairment: Results from the United States Multicenter Trial J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1238 - 1245. [Abstract] [Full Text] [PDF]

				C. Chen, J. Visootsak, S. Dills, and J. M. Graham JR Prader-Willi Syndrome: An Update and Review for the Primary Pediatrician Clinical Pediatrics, September 1, 2007; 46(7): 580 - 591. [Abstract] [PDF]

				P. Marzullo, C. Marcassa, R. Campini, E. Eleuteri, A. Minocci, A. Sartorio, R. Vettor, A. Liuzzi, and G. Grugni Conditional Cardiovascular Response to Growth Hormone Therapy in Adult Patients with Prader-Willi Syndrome J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1364 - 1371. [Abstract] [Full Text] [PDF]

				B. P. Hauffa, K. Haase, I. M. Range, N. Unger, K. Mann, and S. Petersenn The Effect of Growth Hormone on the Response of Total and Acylated Ghrelin to a Standardized Oral Glucose Load and Insulin Resistance in Children with Prader-Willi Syndrome J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 834 - 840. [Abstract] [Full Text] [PDF]

				G. G. Gosman, H. I. Katcher, and R. S. Legro Obesity and the role of gut and adipose hormones in female reproduction Hum. Reprod. Update, September 1, 2006; 12(5): 585 - 601. [Abstract] [Full Text] [PDF]

				S S I Wilson, A M Cotterill, and M-A Harris Growth hormone and respiratory compromise in Prader-Willi Syndrome. Arch. Dis. Child., April 1, 2006; 91(4): 349 - 350. [Abstract] [Full Text] [PDF]

				P. Marzullo, C. Marcassa, R. Campini, E. Eleuteri, A. Minocci, L. Priano, P. Temporelli, A. Sartorio, R. Vettor, A. Liuzzi, et al. The Impact of Growth Hormone/Insulin-Like Growth Factor-I Axis and Nocturnal Breathing Disorders on Cardiovascular Features of Adult Patients with Prader-Willi Syndrome J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5639 - 5646. [Abstract] [Full Text] [PDF]

				C. Pagano, O. Marin, A. Calcagno, P. Schiappelli, C. Pilon, G. Milan, M. Bertelli, E. Fanin, G. Andrighetto, G. Federspil, et al. Increased Serum Resistin in Adults with Prader-Willi Syndrome Is Related to Obesity and Not to Insulin Resistance J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4335 - 4340. [Abstract] [Full Text] [PDF]

				M. Tang-Christensen, N. Vrang, S. Ortmann, M. Bidlingmaier, T. L. Horvath, and M. Tschop Central Administration of Ghrelin and Agouti-Related Protein (83-132) Increases Food Intake and Decreases Spontaneous Locomotor Activity in Rats Endocrinology, October 1, 2004; 145(10): 4645 - 4652. [Abstract] [Full Text] [PDF]

				A. J. van der Lely, M. Tschop, M. L. Heiman, and E. Ghigo Biological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin Endocr. Rev., June 1, 2004; 25(3): 426 - 457. [Abstract] [Full Text] [PDF]

				A. M. Haqq, D. D. Stadler, R. G. Rosenfeld, K. L. Pratt, D. S. Weigle, R. S. Frayo, S. H. LaFranchi, D. E. Cummings, and J. Q. Purnell Circulating Ghrelin Levels Are Suppressed by Meals and Octreotide Therapy in Children with Prader-Willi Syndrome J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3573 - 3576. [Abstract] [Full Text] [PDF]

				D. E. Cummings and M. H. Shannon Roles for Ghrelin in the Regulation of Appetite and Body Weight Arch Surg, April 1, 2003; 138(4): 389 - 396. [Full Text] [PDF]

				A. DelParigi, M. Tschop, M. L. Heiman, A. D. Salbe, B. Vozarova, S. M. Sell, J. C. Bunt, and P. A. Tataranni High Circulating Ghrelin: A Potential Cause for Hyperphagia and Obesity in Prader-Willi Syndrome J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5461 - 5464. [Abstract] [Full Text] [PDF]